Beckman Coulter announced the availability in the United States of its DxH 690T hematology analyzer, which is used as an early sepsis indicator. In addition, this announcement has contributed to the company's increased global presence and growth in revenues.
Prenosis Inc., a precision diagnostics company that uses artificial intelligence to better diagnose patients, renewed its existing agreement with Roche Diagnostics in order to accelerate the detection of sepsis.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 4869
Published Date: Apr 30, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Increasing prevalence of hospital-acquired infections, the rising burden of sepsis in the world, and rising diagnostic developments are the major factors driving the market growth.
The market size of sepsis diagnostics is anticipated to attain a CAGR of 11.90% over the forecast period, i.e., 2023-2035.
High cost of diagnostics devices, and the shortage of skilled healthcare professionals are estimated to be the growth hindering factors for the market expansion.
The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by product, technology, pathogen, testing type, and by region.
The blood culture media segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.